Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GA Depot Phase IIa in RRMS
NCT02212886Phase 2Completed
- Sponsor
- Mapi Pharma
- Start
- Oct 2014
- Primary completion
- May 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Mapi Pharma. Primary endpoint: Safety / Adverse events at 1 year. Started Oct 2014; status: completed.
02
Drugs
glatiramer acetate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02212886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02212886.